

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma ID6155

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
AstraZeneca (acalabrutinib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
African Caribbean Leukaemia Trust	Board of Community Health Councils in
Anthony Nolan	Wales
Black Health Agency for Equality	British National Formulary
Blood Cancer UK	Care Quality Commission
Cancer Black Care	Department of Health - Northern Ireland
Cancer Equality	Healthcare Improvement Scotland
Cancer52	Medicines and Healthcare products
DKMS	Regulatory Agency
Genetic Alliance UK	 National Association of Primary Care
Helen Rollason Cancer Charity	National Pharmacy Association
Independent Cancer Patients Voice	NHS Confederation
Kevin Karawa Leukaemia Trust	Scottish Medicines Consortium
Leukaemia Cancer Society	Welsh Government
Leukaemia Care	Welsh Health Specialised Services
Lymphoma Action	Committee
Macmillan Cancer Support	
Maggie's Centres	Possible comparator companies
Marie Curie	 Accord-UK Ltd (bendamustine)
South Asian Health Foundation	 Aspire Pharma (bortezomib)
Specialised Healthcare Alliance	 Aurobindo Pharma (bortezomib)
Tenovus Cancer Care	Baxter Healthcare Ltd
WMUK	(cyclophosphamide, doxorubicin)
	 Biotech Pharma (bortezomib)
Healthcare professional groups	Celltrion Healthcare UK Ltd (rituximab)
Association of Cancer Physicians	 Dr Reddy's Laboratories UK Ltd
British Geriatrics Society	(bendamustine, bortezomib)
British Institute of Radiology	 Hospira UK Ltd (cytarabine, vincristine)
British Oncology Pharmacy	 Janssen-Cilag Ltd (bortezomib)
Association	 Jazz Pharmaceuticals UK (cytarabine)
British Psychosocial Oncology Society	 medac GmbH (bortezomib, doxorubicin)
British Society for Haematology	 MSN Laboratories Europe (bortezomib)
	Mylan (bortezomib)

Provisional stakeholder list for the evaluation of Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma ID6155



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Society of Interventional Radiology British Transplantation Society Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Cutaneous Lymphoma Group UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Pfizer Ltd (bortezomib, doxorubicin, rituximab) Ranbaxy UK (bortezomib) Roche Products Ltd (rituximab) Sandoz Ltd (bortezomib, cyclophosphamide, rituximab) Seacross Pharmaceuticals Ltd (bendamustine, doxorubicin) Tillomed Laboratories Ltd (bortezomib) Thornton & Ross Ltd (bortezomib) Zentiva Pharma Ltd (bendamustine) Relevant research groups Cochrane Haematology Group Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research
	Associated Public Health groupsPublic Health WalesUK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma ID6155



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.